Compare Gilead Sciences, Inc. (GILD) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $151.02 (market cap $182.40B), while iShares 3 7 Year Treasury Bond ETF trades at $113.45 (market cap $16.72B). The key difference: Gilead Sciences, Inc. is far larger — about 10.9× iShares 3 7 Year Treasury Bond ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares 3 7 Year Treasury Bond ETF for 43 Days on average.
| GILD | IEI | |
|---|---|---|
Market Cap | $182.40B | $16.72B |
Volume | 4,469,821 | 3,963,319 |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $120.72 |
52-Week Low | $116.74 | $113.17 |
Typical Hold Time | 111 Days | 43 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
IEI trades at $113.41, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though oscillators remain neutral. Recent dividend payments of $0.37-0.38 per share provide income stability. The stock faces headwinds from broader bond market volatility as Treasury yields reach multi-decade highs, impacting fixed-income related equities.
The outlook remains cautious amid persistent bond market pressures. While dividend payments offer some support, the bearish technical setup and elevated Treasury yields create near-term challenges. Investment opportunity exists for income-focused investors, but requires careful monitoring of interest rate developments and bond market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
